Legend Biotech names Novartis veteran Ingrid Zhang as new CEO
News from Fierce Pharma: Legend Biotech names Novartis veteran Ingrid Zhang as new CEO
Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.
CARVYKTI Q2 sales update
Earlier-line multiple myeloma data readouts
Solid tumor pipeline expansion
News from Fierce Pharma: Legend Biotech names Novartis veteran Ingrid Zhang as new CEO
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti. | As Legend Biotech became profitable, the company is navigating Carvykti's next phase of growth. Taiho and Cullinan's EGFR candidate delivered a phase 3 win. WuXi AppTec won a preliminary injunction against the Defense Department's black list designation. And more.
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend Biotech CEO resigns; search underway for replacement.
Legend CEO Ying Huang resigns; Carvykti chief named interim leader.
Why Legend Biotech stock fell 10% despite record Carvykti sales.
Chief Executive Officer
Chief Commercial Officer, CARVYKTI
Chief Medical Officer